Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study

Derek J Rosario senior lecturer in cancer studies, J Athene Lane senior research fellow, Chris Metcalfe senior lecturer in medical statistics, Jenny L Donovan professor of social medicine, Andy Doble consultant urological surgeon, Louise Goodwin research nurse and biobanker, Michael Davis research associate in health services research, James W F Catto reader in cancer studies, Kerry Avery research fellow and NIHR post-doctoral award holder, David E Neal professor of surgical oncology, Freddie C Hamdy professor of surgery

1 Academic Urology Unit, Department of Oncology, Royal Hallamshire Hospital, Sheffield, Sheffield S10 2JF, UK; 2 School of Social and Community Medicine, University of Bristol, Bristol BS8 2PS, UK; 3 Department of Urology, Addenbrooke’s Hospital, Cambridge CB2 0QQ, UK; 4 Department of Oncology, University of Cambridge, Addenbrooke’s Hospital; 5 Nuffield Department of Surgical Sciences, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DU, UK

Abstract

Objectives To measure the effect of the adverse events within 35 days of transrectal ultrasound guided biopsy from the perspective of asymptomatic men having prostate specific antigen (PSA) testing; to assess early attitude to re-biopsy; to estimate healthcare resource use associated with adverse events due to biopsy; and to develop a classification scheme for reporting adverse events after prostate biopsy.

Design Prospective cohort study (Prostate Biopsy Effects: ProBE) nested within Prostate Testing for Cancer and Treatment (ProtecT) study.

Participants Between 1999 and 2008, 227 000 community dwelling men aged 50–69 years were identified at 352 practices and invited to counselling about PSA testing. 111 148 attended a nurse led clinic in the community, and 10 297 with PSA concentrations of 3–20 ng/mL were offered biopsy within ProtecT. Between February 2006 and May 2008, 1147/1753 (65%) eligible men (mean age 62.1 years, mean PSA 5.4 ng/mL) having 10 core transrectal ultrasound guided biopsy under antibiotic cover in the context of ProtecT were recruited to the ProBE study.

Outcome measures Purpose designed questionnaire administered at biopsy and 7 and 35 days after the procedure to measure frequency and effect of symptoms related to pain, infection, and bleeding; patients’ attitude to repeat biopsy assessed immediately after biopsy and 7 days later; participants’ healthcare resource use within 35 days of biopsy evaluated by questionnaire, telephone follow-up, and medical note review; each man’s adverse event profile graded according to symptoms and healthcare use.

Results Pain was reported by 429/984 (43.6%), fever by 172/985 (17.5%), haematuria by 642/976 (65.8%), haematochezia by 356/967 (36.8%), and haemoejaculate by 605/653 (92.6%) men during the 35 days after biopsy. Few men rated these symptoms as a major/moderate problem—71/977 (7.3%) for pain, 54/981 (5.5%) for fever, 59/958 (6.2%) for haematuria, 24/951 (2.5%) for haematochezia, and 172/646 (26.6%) for haemoejaculate. Immediately after biopsy, 124/1142 (10.9%, 95% confidence interval 9.2 to 12.8) men reported that they would consider further biopsy a major or moderate problem; seven days after biopsy, this proportion had increased to 213/1085 (19.6%, 17.4% to 22.1%). A negative attitude to repeat biopsy was associated with unfavourable experience after the first biopsy, particularly pain at biopsy (odds ratio 8.2, P<0.001) and symptoms related to infection (7.9, P<0.001) and bleeding (4.2, P<0.001); differences were evident between centres (P<0.001). 119/1147 (10.4%, 8.7% to 12.3%) men reported consultation with a healthcare professional (usually their general practitioner), most commonly for infective symptoms. Complete data for all index symptoms at all time points were available in 851 participants. Symptoms and healthcare use could be used to grade these men as follows: grade 0 (no symptoms/contact) 18 (2.1%, 1.3% to 3.3%); grade 1 (minor problem/no contact) 550 (64.6%, 61.4% to 67.8%); grade 2...
for acute urinary retention),13 in contrast with a reported incidence of "major" complications of 0.1% in an Austrian screened population (n=1051).14 A systematic review of TRUS-Bx observed that only 41 of 87 studies made any mention of adverse events, and where mention was made no standardised approach to reporting was used.15 Furthermore, the acceptability of re-biopsy is uncertain: in the era preceding widespread use of local anaesthesia, a British study reported that 19% of men refused re-biopsy without general anaesthesia,13 and the Finnish study of screening for prostate cancer observed that 18% of screened men would not accept a repeat biopsy.14 In contrast, Djavan et al reported that of 820 Austrian men previously biopsied, all re-attended for re-biopsy as an outpatient when invited.11 The factors influencing this attitude towards repeat biopsy remain uncertain, but it is important as around two thirds of men initially have a negative biopsy and may need another.15 The wide variability in adverse events and acceptability probably reflects a combination of expertise, patients’ expectations, and inconsistent reporting. Little evidence based information about the experience of TRUS-Bx is available to share with men having the procedure. Additionally, no systematic investigation of the acceptability of TRUS-Bx and association between adverse events after TRUS-Bx and attitude to re-biopsy in a PSA-tested population has been done. The aims of this study were to measure the effect of adverse events after a first prostate biopsy in asymptomatic men having PSA testing; to assess early attitudes to repeat biopsy; to estimate the effect of adverse events from TRUS-Bx on healthcare resource use; and to develop a simple classification system for consistent reporting of adverse events after prostate biopsy.

Methods

Design and sample size

A prospective cohort study (ProBE—Prostate Biopsy Effects) was embedded in the ongoing Prostate Testing for Cancer and Treatment (ProtecT) study, which is a large multicentre randomised controlled trial started some years previously to evaluate the effectiveness, cost effectiveness, and acceptability of treatments for men with localised prostate cancer.16 General medical practices in and around nine cities throughout the United Kingdom recruited men to the ProtecT study. Lead partners of the practices received letters of invitation for their practice to participate in the study, detailing the rationale for a randomised controlled trial of treatment in clinically localised prostate cancer detected by PSA. Participating practices in turn sent letters inviting men aged 50-69 years registered at the practice to attend for PSA counselling. Nurse led clinics were held in a primary care setting, where participants with an estimated life expectancy of a minimum of 10 years and without important cardiorespiratory comorbidity were given detailed information about the implications of PSA testing, the uncertainties about treatments, and the need for a treatment trial; consent was sought thereafter for PSA testing. Biopsy was offered to all men with a PSA concentration of 3.0 ng/mL or above. The sample size calculation suggested that 880 participants would provide a precise estimate of an expected hospital admission rate of 1%10 with a 95% confidence interval of 0.4 to 2%. The target was to enrol 1200 men, allowing a priori for a 25% dropout rate.

Population and exposure

In February 2006, the ProBE study started recruitment in eight of the nine ProtecT centres. Men presenting with a PSA concentration of 3.0-19.9 ng/mL, with no previous experience of TRUS-Bx, were invited to participate in ProBE in addition...
to their involvement in the ProtecT study. As many practices were part way through recruitment to ProtecT when ProBE started and stopped recruitment, not all practices nor all men at any given practice were offered the study. The intention was for the ProBE study to recruit consecutive men attending for a prostate biopsy in ProtecT from February 2006 until the sample size of 1200 was reached (see above). Resource limitation at the height of recruitment to ProtecT meant that some biopsy sessions were not covered by research staff, so not all men attending biopsy sessions were offered participation in ProBE.

All men invited to join the ProBE study were given patients’ information sheets on ProBE as well as ProtecT, in addition to local instructions related to the biopsy procedure. Baseline data including weight, height, drug history, comorbidity, Hospital Anxiety and Depression Scale (HADS) score, and urinary, bowel, and sexual symptoms were assessed by using the validated International Continence Society—male, International Consultation on Incontinence Modular Questionnaire—urinary incontinence, and University of California, Los Angeles Prostate Cancer Index questionnaires.\(^ {17} \)\(^ {18} \)\(^ {19} \) Outpatient TRUS-Bx was carried out in the left lateral decubitus position under antibiotic cover by using a 10 core lateral biopsy template.\(^ {20} \)\(^ {21} \) In a pre-study questionnaire, seven of the eight centres reported using periprostatic infiltration of local anaesthetic (1% or 2% lidocaine) routinely before biopsy. All men received antibiotic prophylaxis according to contemporary practice; inter-centre variability existed, but each centre used a consistent schedule throughout the study period. A midstream specimen of urine was sent for culture immediately before antibiotic administration. Coumarin anticoagulant and clopidogrel treatment were discontinued up to 10 days before biopsy and advice sought as to appropriate substitutes if indicated. Aspirin was continued at the discretion of the physician doing the biopsy. Men were kept under observation after the biopsy until they voided. Urine was assessed for haematuria according to a four point colorimetric scale. Each centre provided its own post-biopsy written instructions and contact details.

**Outcome measures**

**Symptoms**

Men self-reported pain and discomfort (referred to as pain hereafter) immediately after and seven days after TRUS-Bx on a four point Likert-type scale as none, mild, moderate, or severe. Specific related complications such as fever, flu-like shivers, pain, haematuria, haematochezia, and haemoejaculate were self-reported at seven and 35 days after TRUS-Bx as absent or present following biopsy on a purpose designed questionnaire (TRUS-BxQ; see appendix 1). This included the validated International Continence Society—male, International Consultation on Incontinence Modular Questionnaire—urinary incontinence, and University of California, Los Angeles Prostate Cancer Index questionnaires.\(^ {17} \)\(^ {18} \)\(^ {19} \) For each reported symptom, participants were asked to grade the degree of “problem” associated with its presence as none, minor, moderate, or major. We used this information to derive a binary outcome for each symptom, as present with moderate/severe problem versus not present/minor problem. During the pilot phase (February 2006 to April 2006), an expert committee (appendix 2) reviewed the initial data from the TRUS-BxQ to optimise face validity and content validity.

**Attitude to re-biopsy**

To assess attitudes to possible further biopsies immediately after the biopsy and seven days later, men were asked to record on a four point Likert-type scale (no problem, minor, moderate, major problem) “how much of a problem would you find having another biopsy in the future?” Analyses explored the relations between men’s reports of pain and symptoms and their attitude to re-biopsy.

**Healthcare resource use**

Men reported any contact with healthcare services in the TRUS-BxQ at seven and 35 days after biopsy. A non-clinical research assistant did semi-structured telephone interviews with men between seven and 10 days after biopsy. When self-reported data were unclear or missing, we searched medical records (written and electronic) for any episode of contact with any provider in primary or secondary care occurring within 35 days of the date of biopsy. We used data from the participants’ interviews, TRUS-BxQ, and the review of hospital records to ascertain the reason for any hospital admission. When contact with primary care was detected or reported, we made an assessment of its relevance to the biopsy procedure, on the basis of a free text description provided by participants in the self-completed TRUS-BxQ and review of the clinical records where necessary.

**Adverse event classification**

We grouped adverse events of fever, flu-like shivers, haematuria, haematochezia, and haemoejaculate together as “infective,” “haemorrhagic,” and combined “infective/haemorrhagic” symptoms. We classified adverse events in a manner consistent with the National Cancer Institute’s common toxicity criteria version 3.0 as grade 0 = no adverse event reported and no biopsy related healthcare contact, grade 1 = symptoms reported but causing no/minor problem and no biopsy related healthcare contact, grade 2 = symptom reported causing major/moderate problem or biopsy related healthcare contact without hospital admission, grade 3 = hospital admission within 35 days of biopsy, and grade 4 = death within 35 days of biopsy.\(^ {22} \) This analysis included only men with a complete dataset of symptoms at both assessments.

**Data analysis**

We used SPSS statistical software version 18.0 to do data analyses using the available data; we did not impute any missing data. We present the proportion of men who experienced each outcome, with 95% confidence intervals calculated by using Wilson’s method (CIA software, version 2.2.0, www.som.southampton.ac.uk/cia). We estimated associations between risk factors and binary outcome measures (for example, moderate/major problem with re-biopsy, healthcare contact, hospital admission) as odds ratios by using logistic regression with adjustment for age and centre. For clarity, where the symptom scale is reduced to a binary distinction, this distinguishes men reporting a moderate/major problem from those reporting a mild/no problem. We used the logistic regression models as the basis of likelihood ratio tests to calculate P values. We adjusted for age and recruitment centre by adding dummy variables to the regression models—three dummy variables distinguishing four age groups (50-54, 55-59, 60-64, and 65-69 years) and seven dummy variables distinguishing eight study centres.
**Results**

In the ProtecT study overall, of the 227,000 men aged 50-69 years who were identified at 352 practices and invited to nurse led clinics in the community for counselling about PSA testing, 111,148 attended. Of the 10,297 men offered TRUS-Bx within ProtecT, 1,753 attended for biopsy between February 2006 and May 2008 and were eligible to enter the ProBE study; 1,147 (65%) consented to participation. Table 1 summarises baseline data.

Of the 1,147 men who had TRUS-Bx within ProBE, TRUS-BxQ data were available for 1,144 (99.7%) at baseline, 1,090 (95.0%) at seven days, and 1,018 (88.8%) at 35 days post-biopsy. Telephone follow-up, primary care, and hospital record data were available for all 1,147 participants. We found no difference between the men recruited in the eight centres with regard to age (P=0.086), PSA concentration (P=0.51), body mass index (P=0.54), or HADS anxiety (P=0.83) or depression scores (P=0.2). A difference in mean prostate volume existed (P<0.001).

**Symptoms, degree of associated problem, and duration**

Immediately after biopsy, 37/1,134 (3.3%, 95% confidence interval 2.4% to 4.5%) men reported light-headedness and three (0.3%, 0.1% to 0.8%) experienced a short period of syncope. All men voided after the procedure. Moderate or severe haematuria was present in 78/1,055 (7.4%, 6.0% to 9.1%) post-biopsy urine samples and was associated with large blood clots in 27 (2.6%, 1.8% to 3.8%). Three additional men passed clots without moderate or severe haematuria.

Table 2 shows the number of men who reported pain, fever, flu-like shivers, haematuria, haematochezia, and haemoejaculate within seven and 35 days of biopsy and the proportion who reported a moderate/major problem associated with each symptom. Approximately one third of men (n=340/1,147) reported no sexual activity within 35 days after biopsy, and the prevalence of haemoejaculate is therefore limited to those who were sexually active during the study period. Although the prevalence of each symptom and combination of symptoms was relatively high, most men reported the presence of a symptom as being no problem or a minor problem (table 2 and box).

**Attitude to repeat biopsy**

Immediately after the procedure, 124/1,142 (10.9%, 9.2% to 12.8%) men reported that having a repeat biopsy would represent a moderate/major problem. This rose to 213/1,085 (19.6%, 17.4% to 22.1%) when the question was repeated seven days later (P=0.001, McNemar’s test for a null hypothesis of no difference in the proportion finding re-biopsy a moderate/major problem). The proportion of men considering repeat biopsy to be a moderate/major problem differed by centre at both time points (P=0.001) (table 3). These differences persisted following the exclusion of centre 3 (P=0.004), where local anaesthetic was not administered routinely.

A strong association existed between an unfavourable attitude to repeat biopsy at seven days and pain reported at both time points (immediately post-biopsy: odds ratio 12.1, P<0.001; at seven days: odds ratio 8.2, P<0.001) as well as symptoms within seven days related to infection (odds ratio 7.89, P<0.001) and bleeding (4.24, P<0.001) (table 4).

**Healthcare contact**

No deaths occurred in this cohort within 35 days of biopsy (95% confidence interval 0 to 0.4%). In that period, 15/1,147 (1.3%, 0.8% to 2.1%) men needed hospital admission for sepsis (n=7), urinary retention (n=3), haematuria (n=2), rectal bleeding (n=1), or other diagnoses (n=2). All admissions due to sepsis occurred within three days of biopsy, whereas one man with retention was admitted three weeks after biopsy. A further 119 (10.4%, 8.7% to 12.3%) men initiated a biopsy related consultation with their general practitioner (n=92), urology department nurse (n=14), or other source of medical advice (13) such as NHS Direct. The predominant reasons for seeking healthcare advice in primary care were infective symptoms (n=38), urinary symptoms including haematuria (34), haemoejaculate (14), possibility of antibiotic related adverse events such as diarrhoea or a skin rash (14), and discomfort/bleeding on defecation (10). We found no evidence that such contacts varied across centres (P=0.73).

Table 4 lists selected variables examined for associations with healthcare contact within 35 days. Biopsy related healthcare contact within 35 days was more likely in men with a previous history of urinary tract infection (P=0.036) compared with others, and in men who reported moderate/severe pain immediately after the procedure (P=0.017). Cross sectional analysis showed a strong association between healthcare contact and symptoms of infection, bleeding, or both at seven days (P<0.001).

Owing to the low number of events, we could investigate only crude associations with hospital admissions. We found evidence of a higher risk of hospital admission in men treated with non-steroidal agents (3/58 (5%) v 11/1035 (1.1%), P=0.037) and those reporting a moderate/severe problem with symptoms of infection (7/47 (15%) v 7/1036 (0.7%), P<0.001) or bleeding (6/179 (3%) v 9/843 (1.1%), P=0.039) at 7 days. None of the men with a history of prostatitis (n=18) or warfarin treatment (n=14) or who had an infected midstream urine sample before biopsy (n=18) were admitted to hospital within 35 days of the procedure.

**Adverse event classification**

Complete data on the five index symptoms at seven and 35 days were available for 851/1,147 (74.2%) men. We classified adverse events as grade 0 (no symptoms/contact) in 18 (2.1%, 1.3% to 3.3%), grade 1 (minor) in 550 (64.6%, 61.4% to 67.8%), grade 2 (moderate/major) in 271 (31.8%, 28.8% to 35.1%), and grade 3 (inpatient/hospital admission) in 12 (1.4%, 0.8% to 2.4%); no participants had a grade 4 event (death). We found strong evidence of an association between the grade of adverse event at 35 days and an unfavourable attitude to repeat biopsy at seven days (Kendall’s τ-b ordinal by ordinal 0.29, P<0.001).

**Exploratory analyses**

**Prostate volume, age, and attitude to repeat biopsy**

We found weak evidence that older men were more likely to report a favourable attitude to repeat biopsy than were younger participants (odds ratio per 5 year increase in age between 50 and 69 years: 0.86, 0.75 to 1.00, P=0.056) (table 4). Men who considered repeat biopsy to be a moderate/major problem were more likely to have a smaller prostate volume (P=0.027) (table 4).
Prostate cancer diagnosis and healthcare contact

Prostate cancer was diagnosed on biopsy in 406/1147 (35.4%, 32.6% to 38.2%) men. We found a difference in cancer detection rates ranging between 23% (14% to 36%) and 53% (40% to 65%) across the eight centres (P=0.008). We found no convincing evidence that men subsequently diagnosed as having cancer were more likely to come into contact with healthcare services for a biopsy related adverse event within 35 days of the procedure compared with men in whom cancer was not diagnosed (48/406 (11.8%) v 87/741 (11.6%); odds ratio 1.03, 0.70 to 1.50, P=0.89, adjusted for age and study centre). The risk of hospital admission was 1.7% in men subsequently diagnosed as having cancer and 1.1% in those without cancer (P=0.84).

Discussion

This multicentre prospective study with a high response rate of 89% at 35 days provides generalisable quantitative data about the events occurring in the 35 days after a first prostate biopsy. The findings are based on patient reported outcomes and verifiable criteria, including healthcare resource use. Whereas prostate biopsy was reasonably well tolerated in most men, a few men rated post-biopsy pain and infective/haemorrhagic symptoms as a major/moderate problem—7.3% for pain, 5.5% for fever, 6.2% for haematuria, 2.5% for haematochezia, and 26.6% for haemoejaculate. Immediately after biopsy, 10.9% reported that they would consider further biopsy a major or moderate problem; seven days after biopsy, this proportion had increased to 19.6%. A negative attitude to repeat biopsy was associated with unfavourable experience after the first biopsy, particularly pain at biopsy; differences were evident between centres carrying out the biopsies. Consultation with a healthcare professional (usually their general practitioner) was reported by 10.4%, most commonly for infective symptoms.

Transrectal ultrasound guided biopsy of the prostate is an ambulatory procedure commonly carried out in consulting rooms and outpatient and radiology departments in small and large hospitals. Although accurate figures for the number of procedures carried out in the UK each year are difficult to elicit, approximately 37 000 new cases of prostate cancer are diagnosed annually (http://info.cancerresearchuk.org/cancerstats/types/prostate), with a cancer detection rate at biopsy of around 35%. Assuming that around 100 000 procedures are carried out every year in the UK alone would thus be reasonable.

The results of this study are particularly relevant to screening for prostate cancer rather than the performance of prostate biopsy for confirmation of a diagnosis in clinically evident disease. The cohort is drawn from asymptomatic men, invited for PSA testing in the context of a large randomised controlled trial (ProtecT), with a first biopsy at a PSA concentration of 3.0-19.9 ng/mL, a range commonly held to be appropriate for detection of localised prostate cancer suitable for treatment with curative intent. None of the men had repeat biopsy during the timeframe specified. Particular emphasis was placed on the perception of the man having the biopsy, as well as the identification of adverse events. This emphasis allowed the study to measure how a man perceives the degree of “problem” associated with individual symptoms resulting from a first prostate biopsy. Cross referencing these perceptions with healthcare resource use provided useful triangulation. Maintaining a high response rate of 95% at seven days and 89% at 35 days is a particular strength of the study.

A significant number of men experienced difficulties during or after the biopsy, primarily associated with pain, sepsis, or bleeding. Very few men experienced no symptoms at all (2.1%, grade 0) in the five weeks after biopsy. Of those who did experience one or more symptoms, most considered them to be of little consequence (64.6%, grade 1). The remaining third experienced adverse events that they considered to be a moderate or severe problem. Of interest, the presence of blood in a man’s ejaculate (haemoejaculate) after biopsy is seldom reported in the literature and is often labelled as a “minor” adverse event. In this study, haemoejaculate was perceived as a moderate to severe problem for around one quarter of sexually active men (table 2). Further investigation of the problems generated by this symptom is warranted, and information about its duration and persistence should be given to all men having biopsies.

During initial counselling before PSA testing, men are informed of the possible requirement for repeat biopsies beyond the first procedure, in the event of equivocal results or a benign biopsy.
with persistent risk factors such as a persistently raised serum PSA concentration. A recent study from the United States reported that 38% of men having a first biopsy will have a repeat procedure within five years of the initial biopsy; the proportion reaches 44% in men under the age of 70 years. Several studies have shown that repeat biopsy leads to a detection rate for prostate cancer of 19-59%, indicating the efficacy of a single dose of ciprofloxacin in reducing the incidence of infective complications after TRUS-Bx. Subsequent studies have suggested that prolonging treatment to three days results in superior clinical effectiveness. A recent report has identified an increasing rate of sepsis related admission to hospital after prostate biopsy in the decade between 1996 (0.6%) and 2005 (3.6%). The association between levels of pain experienced and attitude to having repeat biopsy described in this study is an important observation that supports the mandatory use of periprostatic nerve blockade with local anaesthetic. Even among centres where local anaesthetic was routinely administered, inter-centre variability in its effect existed. This suggests that the technique of administration may need to be standardised to ensure effectiveness of local anaesthesia.

As well as resulting in a negative attitude to re-biopsy, infective complications were the most common reason for seeking medical advice or primary care intervention (10.4%). Most symptoms were evident within seven days of biopsy, with a small proportion of men continuing to report symptoms for up to five weeks after biopsy (box). This information is particularly valuable for general practitioners when counselling patients before PSA testing. The American Urological Association’s best practice policy statement recommends administration of a fluoroquinolone as uniform antimicrobial prophylaxis in all men having TRUS-Bx. Current practice, however, has been influenced predominantly by randomised controlled trials indicating the efficacy of a single dose of ciprofloxacin in reducing the incidence of infective complications after TRUS-Bx; subsequent studies have suggested that prolonging treatment to three days results in superior clinical effectiveness. A recent report has identified an increasing rate of sepsis related admission to hospital after prostate biopsy in the decade between 1996 (0.6%) and 2005 (3.6%). This may be related to a general reduction in peri-biopsy antibiotic use, but the development of quinolone resistance may also be implicated. Against this backdrop, antibiotic prophylaxis for TRUS-Bx is universally used, but without consensus on best practice. We have shown some evidence of differences in infective complications between centres, but our study was not specifically designed to evaluate the effectiveness of antibiotic prophylaxis; this warrants further prospective investigation.

The classification of adverse events described in this study is similar to that described after systemic chemotherapy. It is based on a combination of reported events and their effect from a patient’s perspective. Its wider use needs further validation and is likely to show the need to standardise and refine the technique of prostate biopsy to minimise its adverse events. No fatal events occurred in our cohort. This is not surprising, as our participants were relatively healthy with an upper age limit of 69 years and no symptoms. Mortality after prostate biopsy has been reported as ranging between 0.09% and 1.3% at 120 days, and it is associated with older, less healthy men.

In contrast with a large retrospective Canadian study referred to earlier, we found no difference in our prospective study in hospital admission rate (grade 3 adverse event) between participants with cancer and those without (1.7% vs 1.1%). The findings of the study may result from the investigation of a population at different risk or, as acknowledged by the authors, from inaccuracy in coding associated with its retrospective nature.

**Limitations of study**

The ProBE study cohort included asymptomatic men aged between 50 and 69 years presenting for a first prostate biopsy after a PSA test, received through the ProtecT study during the period February 2006 to May 2008. The ProBE study was carried out over this limited period, sampling approximately 11% of the ProtecT participants. The cohort did not include men seen in routine UK clinical practice with urinary symptoms or clinically suspected prostate cancer. Of the men eligible for inclusion, 65% were recruited and thus are likely to be representative of the men who attended for PSA testing within the ProtecT study. Embedding the ProBE study in the ProtecT trial was beneficial, providing a standardised biopsy template and recruitment from a wide range of practices across the UK and improving compliance with follow-up. However, participants had responded to a single written invitation to attend for PSA testing sent out via general practices, so non-responders may not be represented in this study. The observations are likely to remain valid in the context of men seeking PSA testing for detection of prostate cancer.

In the absence of nationally agreed, evidence based patient information leaflets, each centre delivered its own information about the biopsy process, which may have influenced men’s views. Recall bias may also have occurred for recording the duration of symptoms, as men were asked to summarise their experience over the previous four weeks in the 35 day questionnaire. For the main analyses, we required data with evaluable responses from both the seven day and 35 day questionnaire assessments. This reduced the numbers and may have led to some degree of underestimation of the prevalence of adverse events. Although relevant to the overall outcome, some of the reported symptoms (such as fever/shivers) may not have been related to the biopsy itself and may have inadvertently influenced a negative attitude to repeat biopsy.

**Additional items**

Administration of local anaesthesia is important in determining pain experienced, but other factors, such as environment, training, education, and nursing care, will clearly affect anxiety and pain. We have explored some of these factors in a linked qualitative study (data not included). Similarly, although we have sought men’s initial and early views on the acceptability of repeat biopsy, attitudes may change with time; we shall therefore follow up this cohort carefully to analyse the re-biopsy rate and assess patients’ subsequent views.

While healthcare providers await further evidence to decide whether screening for prostate cancer should become public health policy, primary care physicians need to be well informed of the risks and adverse events related to TRUS-Bx as well as PSA before testing. The findings of this study contribute further generalisable quantitative data about the potential harms associated with making a diagnosis of prostate cancer in asymptomatic men.
Generalisability

The ProBE study investigated a large cohort of men aged between 50 and 69 years who had TRUS-Bx for the first time as a result of a PSA concentration between 3.0 and 20 ng/mL. The cohort comprised 65% of eligible men biopsied within a trial population. The results are likely to be generalisable to all asymptomatic men in this age group who seek diagnosis of prostate cancer through PSA testing and in the context of screening. They may, however, not be applicable to younger or older men, those with clinical evidence of prostate cancer, or men who have previously had prostate biopsy.

Conclusions

After prostate biopsy, one third of men having first time TRUS-Bx for a high PSA reported moderate to severe biopsy related symptoms. Immediately after TRUS-Bx, one in 10 men had an unfavourable attitude to repeat biopsy, rising to one in five had. This was associated with adverse events in the seven days after biopsy and seemed to affect younger men more; as these men are most likely to benefit from early diagnosis of prostate cancer as well as require re-biopsy, this requires further investigation. Within 35 days of biopsy, 1.3% of men required admission to hospital and a further 119 (10.4%) men initiated a biopsy related consultation with their general practitioner (n=92), urology department nurse (n=14), or other source of medical advice (n=13) such as NHS Direct, most commonly for infective symptoms. The adverse event classification scheme described may help to show variation in rates of adverse events across centres that arise from differences in information and biopsy technique. Training, protocols, and consistent reporting methods should be considered to achieve excellence in practice. Information for patients about biopsy should be standardised and include the findings of this study, so that men and physicians are fully informed about the risks and benefits of the diagnostic process before they embark on prostate cancer detection.

The ProBE (Prostate Biopsy Effects) Study Group: Prasad Bollina, Sue Bonnington, Lynn Bradshaw, Debbie Cooper, Liz Down, Alan Doherty, Garrett Durkan, Emma Elliott, David Gillatt, Pippa Herbert, Peter Holding, Joanne Howson, Mandy Jones, Roger Kockelbergh, Howard Kynaston, Teresa Lennon, Norma Lyons, Hing Leung, Malcolm Mason, Hilary Moody, James N’Dow, Philip Powell, Alan Paul, Stephen Prescott, Patricia O’Sullivan, Pauline Thompson, and Sarah Tibbald.

Contributors: DJR, JAL, and FCH devised the protocol and arranged funding body. The ProtecT study is funded by NIHR HTA. Management Group. The study and authors are independent of the intellectual content. DJR and JAL are the guarantors. DJR and JAL advised on research priorities, advised on integration as medical consultant to the study. KA carried out the preliminary questionnaire, and acted as nurse consultant to the study. MD contributed to study design and particularly advised on questionnaire validation. AD contributed to study design and acted as medical consultant to the study. LG contributed to study design, carried out the validation of the TRUS-Bx questionnaire, and acted as nurse consultant to the study. MD contributed to study design and dealt with data queries. JWFC acted as medical consultant to the study. KA carried out the preliminary qualitative study that highlighted areas of concern and contributed to study design. DEN advised on research priorities, advised on integration into the ongoing ProtecT study, and contributed to study design. All authors critically revised the manuscript and revised it for important intellectual content. DJR and JAL are the guarantors.

Funding: The ProBE study was funded by the Prostate Cancer Risk Management Group. The study and authors are independent of the funding body. The ProtecT study is funded by NIHR HTA.

Competing interests: All authors have completed the Unified Competing Interest form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; and no other relationships or activities that could appear to have influenced the submitted work.

Ethical approval: The ProBE study received approval from Trent MREC as part of the ProtecT (Prostate Testing for Cancer and Treatment) trial (ISRCTN20141297).

Data sharing: No additional data available for sharing.
What is already known on this topic
Prostate biopsy is essential for diagnosis of prostate cancer, but its acceptability and effects have rarely been investigated prospectively.

Prostate biopsy is thought to be well tolerated, but little is known about the effect of adverse events on men, their attitude to re-biopsy, or their subsequent use of healthcare resources.

Prostate biopsy can be associated with considerable morbidity, including sepsis, pain, bleeding, and even mortality, but at unknown rates owing to variable reporting.

What this study adds

At seven days after biopsy, 39% of men had pain, 12% had fever, 64% had haematuria, 33% had rectal bleeding, and 94% of those who were sexually active had haemoejaculate; all symptoms were less prevalent at 35 days.

Men rated only a small proportion of these events as serious, with the exception of haemoejaculate in those who were sexually active, with one in four describing this as a moderate/major problem.

Immediately after a first biopsy, one in 10 men had an unfavourable attitude to a repeat procedure, increasing to one in five at seven days.

After a first biopsy, one in 10 men sought help from primary care, and one in 100 needed hospital admission within 35 days of the procedure.

30 Ingber MS, Ibrahim I, Turzewska C, Hollander JB, Diokno AC. Does periprostatic block reduce pain during transrectal prostate biopsy? A randomized, placebo-controlled, double-blinded study. Int Urol Nephrol 2010;42:23-7.
31 Wolf JS Jr, Bennett CJ, Dmochowski RR, Holtenbock BK, Paerle MS, Schaeffer AJ, et al. Best practice policy statement on urologic surgery antimicrobial prophylaxis. J Urol 2008;179:1379-90.
32 Aron M, Rajeev TP, Gupta NP. Antimicrobial prophylaxis for transrectal needle biopsy of the prostate: a randomized controlled study. BJU Int 2003;89:862-9.
33 Kapoor OA, Klimberg IW, Malek GH, Wogenka JD, Cox CE, Patterson AL, et al. Single-dose oral ciprofloxacin versus placebo for prophylaxis during transrectal prostate biopsy. Urology 1998;52:552-8.
34 Schaeffer AJ, Montorsi F, Scattoni V, Pernonol R, Song J, Havestorm DC, et al. Comparison of a 3-day with a 1-day regimen of an extended-release formulation of ciprofloxacin as antimicrobial prophylaxis for patients undergoing transrectal needle biopsy of the prostate. BJU Int 2007;100:51-7.
35 Nam RK, Saska R, Lee Y, Liu Y, Law C, Klotz LH, et al. Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. J Urol 2010;183:963-8.
36 Sexton WJ. Editorial comment. J Urol 2010;183:969.
37 Cannon GM Jr, Smaldone MC, Paterson DL. Extended-spectrum beta-lactamase gram-negative sepsis following prostate biopsy: Implications for use of fluoroquinolone prophylaxis. Can J Urol 2007;14:3653-5.
38 Carlson WH, Bell DG, Lawen JD, Rendon RA. Multi-drug resistant E.coli sepsis in physicians following transrectal ultrasound guided prostate biopsies—three cases including one death. Can J Urol 2010;17:5135-7.
39 Chappeil B, O’Brien T. Infections after prostate biopsy and antibiotic resistance. BJU Int 2009;103:409.
40 Thompson PM, Phippott-Howard J, Wang W. Is the current antibiotic prophylaxis policy in transrectal prostate biopsy still safe? BJU Int 2009;104:217-2.
41 Burdien HP, Ranaaljinge W, Parsad R. Antibiotics for transrectal urosonography-guided prostate biopsy: are we practising evidence-based medicine? BJU Int 2008;101:1302-4.
42 Gallina A, Suard N, Montorsi F, Capitanio U, Jeldres C, Saad F, et al. Mortality at 120 days after prostatic biopsy: a population-based study of 22,175 men. Int J Cancer 2008;123:947-52.

Accepted: 13 October 2011

Cite this as: BMJ: 2012;344:d7894

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non-commercial and is otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-nc/2.0/ and http://creativecommons.org/licenses/by-nc/2.0/legalcode.
Table 1 | Summary statistics for baseline measures overall and at each centre

| Characteristics | Total cohort | Centre number | P value for between centre differences |
|-----------------|-------------|---------------|---------------------------------------|
|                 |             | 1  | 2  | 3  | 4  | 5  | 6  | 7  | 8  |
| No of biopsies  | 1147        | 282| 206| 176| 149| 115| 102| 56 | 61 |
| Mean (SD) age (years) | 62.1 (5.1)  | 62.0 (5.0)| 62.8 (4.6)| 61.2 (5.4)| 61.8 (5.1)| 61.9 (4.9)| 62.5 (5.1)| 62.2 (5.7)| 62.9 (5.1)| 0.09* |
| Median (interquartile range) PSA (ng/mL) | 4.2 (3.5 to 5.8) | 4.3 (3.5 to 5.8) | 4.3 (3.5 to 5.8) | 4.2 (3.4 to 5.4) | 4.2 (3.5 to 5.8) | 4.1 (3.5 to 5.8) | 4.3 (3.5 to 5.8) | 4.8 (3.6 to 5.8) | 4.1 (3.4 to 5.8) |
| Mean (SD) body mass index (kg/m²) | 27.4 (3.6) | 27.3 (3.8) | 27.1 (3.3) | 27.9 (3.4) | 27.1 (3.6) | 27.8 (3.8) | 27.7 (3.7) | 28.1 (4.4) | 27.5 (3.2) | 0.54* |
| Mean (SD) HADS (anxiety) | 4.9 (3.3) | 4.8 (3.2) | 5.0 (3.4) | 5.2 (3.3) | 4.8 (3.6) | 4.6 (2.7) | 4.9 (3.2) | 4.5 (2.9) | 4.9 (3.5) | 0.83* |
| Mean (SD) HADS (depression) | 3.1 (2.7) | 3.2 (2.5) | 3.3 (2.7) | 3.4 (2.8) | 3.0 (2.8) | 2.7 (2.5) | 3.1 (2.4) | 2.4 (2.2) | 3.3 (2.9) | 0.2* |
| Median (interquartile range) prostate volume (mL) | 38 (28 to 52) | 38 (30 to 53) | 47 (34 to 66) | 31 (24 to 43) | 44 (32 to 65) | 32 (27 to 38) | 31 (24 to 41) | 42 (35 to 57) | 46 (36 to 55) | <0.001† |

HADS=Hospital Anxiety and Depression Scale; PSA=prostate specific antigen.

*From ordinary least squares regression.
†From non-parametric comparison of medians.
## Table 2: Specific symptoms—prevalence and association with moderate or severe problem within 7 days and within 35 days

| Symptom reported | Reporting/respondents % (95% CI) | MS/respondents % (95% CI) | Symptom present | Moderate/serious problem (MS)* |
|------------------|----------------------------------|---------------------------|------------------|-------------------------------|
| **Within 7 days**|                                  |                           |                  |                               |
| Pain             | 425/1089 39.0 (36.2 to 42.4)     | 62/1085 5.7 (4.4 to 7.3)  |                  |                               |
| Fever            | 128/1090 11.7 (10.0 to 13.8)     | 44/1088 4.0 (3.0 to 5.4)  |                  |                               |
| Shivers          | 135/1089 12.4 (10.6 to 14.5)     | 35/1086 3.2 (2.3 to 4.5)  |                  |                               |
| Haematuria       | 693/1085 63.9 (61.0 to 66.7)     | 52/1074 4.8 (3.6 to 6.3)  |                  |                               |
| Haematochezia    | 354/1076 32.9 (30.0 to 35.6)     | 18/1061 1.7 (1.0 to 2.7)  |                  |                               |
| Haemoejaculate†  | 645/747 86.3 (83.7 to 88.6)      | 148/740 20.0 (17.2 to 23.1)|                  |                               |
| Any infective/haemorrhagic symptom‡ | 691/735 94.0 (92.1 to 95.5) | 160/714 22.4 (19.5 to 25.6) |                  |                               |
| Any infective/haemorrhagic symptom§ | 936/1047 89.4 (87.4 to 91.1) | 196/1013 19.3 (17.0 to 21.9) |                  |                               |
| **Within 35 days†** |                                  |                           |                  |                               |
| Pain             | 429/984 43.6 (40.5 to 46.7)      | 71/977 7.3 (5.7 to 9.1)   |                  |                               |
| Fever            | 172/985 17.5 (15.2 to 20.0)      | 54/981 5.5 (4.2 to 7.1)   |                  |                               |
| Shivers          | 185/985 18.8 (16.5 to 21.3)      | 49/979 5.0 (3.7 to 6.6)   |                  |                               |
| Haematuria       | 642/976 65.8 (62.7 to 68.7)      | 59/958 6.2 (4.7 to 7.9)   |                  |                               |
| Haematochezia    | 356/967 36.8 (33.8 to 39.9)      | 24/951 2.5 (1.6 to 3.7)   |                  |                               |
| Haemoejaculate†  | 605/653 92.6 (90.4 to 94.4)      | 172/646 26.6 (23.3 to 30.2)|                  |                               |
| Any infective/haemorrhagic symptom‡ | 622/642 96.9 (95.2 to 98.0) | 181/610 29.7 (26.2 to 33.4) |                  |                               |
| Any infective/haemorrhagic symptom§ | 881/937 94.0 (92.3 to 95.4) | 240/887 27.1 (24.2 to 30.1) |                  |                               |

*Presence of symptom causing moderate or severe problem.
†Excludes 339 men reporting no sexual activity at either 7 or 35 day assessment.
‡One or more of fever, shivers, haematuria, haematochezia, and haemoejaculate, excluding men reporting no sexual activity at either 7 or 35 day assessment.
§One or more of fever, shivers, haematuria, haematochezia, and haemoejaculate, excluding men reporting no sexual activity at either 7 or 35 day assessment.
¶Includes only men with evaluable data for both 7 day and 35 day assessments.
### Table 3: Pain and report of attitude to re-biopsy across eight study centres

| Centre | No of biopsies | Immediate report | 7 day report: problem with re-biopsy |
|--------|----------------|------------------|-------------------------------------|
|        |                | Pain             | Problem with re-biopsy              |                                |
|        |                | MS/response* % (95% CI) | MS/response* % (95% CI) | MS/response* % (95% CI) |
| 1      | 282            | 21/282 7 (5 to 11) | 23/281 8 (6 to 12) | 30/270 11 (8 to 15) |
| 2      | 206            | 37/205 18 (13 to 24) | 22/206 11 (7 to 16) | 38/192 20 (15 to 26) |
| 3      | 176            | 63/174 36 (30 to 44) | 37/176 21 (16 to 28) | 50/168 30 (23 to 37) |
| 4      | 149            | 9/147 6 (3 to 11) | 9/147 6 (3 to 11) | 21/136 15 (10 to 23) |
| 5      | 115            | 16/113 9 (9 to 22) | 9/113 8 (4 to 14) | 23/109 21 (15 to 30) |
| 6      | 102            | 11/102 11 (6 to 18) | 9/102 9 (5 to 16) | 17/96 18 (11 to 27) |
| 7      | 56             | 8/56 14 (7 to 26) | 8/56 14 (7 to 26) | 19/55 35 (23 to 48) |
| 8      | 61             | 7/61 11 (6 to 22) | 7/61 11 (6 to 22) | 15/59 25 (16 to 38) |
| Total  | 1147           | 172/1140 15.1 (13.1 to 17.3) | 124/1142 10.9 (9.2 to 12.8) | 213/1085 19.6 (17.4 to 22.1) |

P value† | <0.001 | <0.001 | <0.001

*Number of men reporting moderate or severe problem/number responding.
†Age adjusted test of null hypothesis (no between centre difference).
| Factors                              | Summary statistics in predictors for overall cohort | Problem with re-biopsy | Healthcare contact |
|-------------------------------------|----------------------------------------------------|------------------------|--------------------|
|                                     | Odds ratio (95% CI) P value*                        | Odds ratio (95% CI)    | P value*           |
| Pain of biopsy                      | 172/1140 (15.1%)                                   | 8.20 (5.54 to 12.13)   | <0.001             |
|                                     |                                                    | 1.81 (1.13 to 2.90)    | 0.017              |
| Infective symptoms at 7 days        | 47/1083 (4.3%)                                     | 7.89 (4.16 to 14.94)   | <0.001             |
|                                     |                                                    | 16.78 (8.73 to 32.27)  | <0.001             |
| Haemorrhagic symptoms at 7 days     | 179/1022 (17.5%)                                   | 4.24 (2.92 to 6.15)    | <0.001             |
|                                     |                                                    | 2.89 (1.88 to 4.44)    | <0.001             |
| Age (odds ratio per 5 years)        | Mean 62.1 (SD 5.1) years (n=1147)                  | 0.86 (0.75 to 1.00)    | 0.056              |
|                                     |                                                    | 1.11 (0.93 to 1.34)    | 0.25               |
| Prostate volume (odds ratio per 20 mL) | Mean 43.5 (SD 22.8) mL (n=1062)                   | 0.82 (0.69 to 0.99)    | 0.027              |
|                                     |                                                    | 1.16 (0.99 to 1.37)    | 0.072              |
| History of urinary tract infection  | 81/1097 (7.4%)                                     | 0.96 (0.62 to 1.79)    | 0.91               |
|                                     |                                                    | 1.99 (1.08 to 3.65)    | 0.036              |
| History of prostatitis              | 18/1094 (1.6%)                                     | 1.41 (0.47 to 4.18)    | 0.55               |
|                                     |                                                    | 2.99 (1.02 to 8.76)    | 0.065              |
| Positive midstream urine at biopsy  | 18/1078 (1.7%)                                     | 1.15 (0.32 to 4.15)    | 0.84               |
|                                     |                                                    | 2.69 (0.93 to 7.80)    | 0.091              |
| Warfarin treatment                  | 14/1091 (1.3%)                                     | 0.38 (0.05 to 3.00)    | 0.30               |
|                                     |                                                    | 2.99 (0.91 to 9.85)    | 0.097              |
| Haematuria/clots in first voided urine | 81/1055 (7.7%)                                      | 1.04 (0.59 to 1.85)    | 0.89               |
|                                     |                                                    | 1.12 (0.56 to 2.22)    | 0.75               |
| Aspirin treatment                   | 244/1096 (22.3%)                                   | 0.87 (0.58 to 1.29)    | 0.48               |
|                                     |                                                    | 0.87 (0.54 to 1.39)    | 0.55               |
| NSAID treatment                     | 58/1093 (5.3%)                                     | 0.68 (0.32 to 1.43)    | 0.29               |
|                                     |                                                    | 0.85 (0.35 to 2.04)    | 0.71               |

Odds ratios and P values are adjusted for age and centre.

NSAID = non-steroidal anti-inflammatory drug.

*Calculated with likelihood ratio tests.